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Quantitative proteomic analysis of Stratum Corneum 
dysfunction in adult chronic Atopic Dermatitis
Jason Winget1, Deborah Finlay2, Kevin J. Mills2, Tom Huggins2, Charles Bascom2, Robert 
J. Isfort2, and Robert L. Moritz1
1Institute for Systems Biology, Seattle, Washington
2The Procter & Gamble Company, Cincinnati, Ohio
To the Editor
Atopic Dermatits/Eczema (AD) is a common condition in childhood and is also suffered by 
approximately 2–3% of adults (Eichenfield et al., 2014). Despite intense scientific 
investigation into the genetics of AD, disease-linked loci are associated with a minority of 
disease cases (Baurecht et al., 2015), leaving the etiology of spontaneous AD in question.
To better understand the biology of AD and to identify protein markers of disease, we 
applied quantitative techniques to identify differential Stratum Corneum (SC) proteins from 
adult AD patients and normal individuals. Using discovery proteomics we identified over 
1000 proteins in the SC, with over 200 differentially identified by condition. Selected 
proteins were quantified with precise targeted methods. Technical details are described in the 
Supplementary Materials and Methods (online).
Specifically, we profiled skin surface tape strip samples from 11 AD subjects at lesional and 
nonlesional sites. These were compared with similar samples from 17 healthy subjects. 
Combining all spectral evidence, we identified 1102 proteins at a 1% false positive error rate 
(FPER). This represents the most comprehensive proteomic study of AD stratum corneum to 
date (Broccardo et al., 2011, Sakabe et al., 2014). The full identification list can be found in 
Supplementary File S1.
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A poorly characterized aspect of skin biology is the role of protein post-translational 
modifications which are abundant in the outer layers of the epidermis. One such is 
modification is citrullination (conversion of arginine to citrulline, also called deimination) 
(Gyorgy et al., 2006). We included citrullination in our search parameters and filtered the 
results to avoid false positives. We detected at least one citrullination site on 1005 proteins 
(91% of those identified). The most citrullinated proteins were trichohyalin and filaggrin, 
which are known to be heavily modified in vivo. For filaggrin, healthy and nonlesional 
atopic skin were citrullinated on 78% and 75% of arginine residues, respectively. This 
decreased to 62% in lesional skin, corresponding to a loss of modification on 56 residues. Of 
the 386 proteins that were citrullinated in all conditions, 257 exhibit decreased fractional 
citrullination in lesional sites compared to other conditions (Figure 1). Notably, trichohyalin, 
an abundant hair protein not considered related to AD, showed a negligible difference by the 
same comparison.
We next analyzed differential proteins by two methods: Fisher’s exact test on identification 
counts by condition and Student’s t-test on label-free quantification results for proteins 
observed in greater than 10 samples (Figure 2A & 2B, repectively). 252 proteins were 
differentially observed between healthy and AD samples (Figure 2A & Supplementary File 
S1). Many were general plasma-related markers of inflammation. Preferentially observed in 
AD included proteins related to inflammation and barrier function such as serpins A3, B4, & 
B5, interleukin-1 receptor antagonist, interleukin-36 receptor antagonist, protein disulfide 
isomerases, and S100s A4 & A6. In addition, 36 proteins were found as differentially 
abundant via t-test (Figure 2B). These include inflammation-related proteins such as serpins 
A1, B3, & B12 and S100s A8, A9, and A11. Proteins down-regulated in AD skin are 
generally structural, including several keratins as well as filaggrin-2. Fillagrin-2 was only 
annotated in 2009 (Wu et al., 2009) and mutations have been recently linked to persistent 
AD (Margolis et al., 2014). When comparing nonlesional and lesional AD samples, 45 
proteins are differentially observed (Figure 2A & Supplementary File S1). 16 are 
preferentially found at the lesional site while 29 are observed more frequently in nonlesional 
samples. The protein most preferentially identified at the lesional site was PYCARD, a key 
regulator of inflammasome and activation and apoptosis (Martinon et al., 2002). One protein 
found at the majority of nonlesional sites but only at 9% of lesional sites was SPINK5, a 
gene with mutations linked to AD in Japanese patients (Kato et al., 2003).
To confirm results from discovery LC-MS/MS, we targeted several AD-related proteins 
using more sensitive and precise Selected Reaction Monitoring (SRM) mass spectrometry-
based assays. These results support our shotgun LC-MS/MS label-free quantification, but 
with increased sensitivity as expected. Caspase 14, beta-defensin, desmoglein-1, 
desmoplakin, filaggrin, kallikrein-8, keratin 10, S100-A7, and S100-A9 all increase when 
comparing healthy to atopic nonlesional skin. In addition, beta-defensin, filaggrin, S100-A7, 
and S100-A9 further increase from nonlesional to lesional atopic skin. The only targeted 
protein to show a significant decline is filaggrin-2, which decreases substantially from 
nonlesional compared to lesional epidermis, in agreement with label-free quantification 
above. Given the evidence for reduced abundance of filaggrin in atopic dermatitis from 
several studies (Suarez-Farinas et al., 2011, Pellerin et al., 2013), our observation of 
increased SRM signal in atopic skin may seem counterintuitive. Our label-free quantification 
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found filaggrin to be similar between healthy and AD (p=0.2, supplementary file S1). It is 
important to consider that in the targeted SRM assay we are monitoring SRM signal from 
the fully tryptic unmodified peptide, 3976HGSYGSADYDYGESGFR3992. In addition to the 
mass shift introduced by citrullination, we observed that this modification typically results in 
a missed cleavage at arginine, rendering the peptide invisible to the SRM assay deployed 
here. Thus our observation is consistent with decreased citrullination on the endogenous 
peptide as disease progresses. Indeed, the majority of evidence for filaggrin protein loss 
comes from immunohistochemistry experiments where antibody epitopes are not always 
characterized. It is possible that these epitopes are citrullinated, similar to those observed in 
vivo for rheumatoid arthritis (Girbal-Neuhauser et al., 1999).
While genetic factors tied to AD have been investigated in some detail, these account for a 
minority of disease incidence (Baurecht and Hotze, 2015). Much focus has been directed 
toward filaggrin loss-of-function mutations, however transcriptomic profiles stratified by 
filaggrin mutation status demonstrate an up-regulation of this protein in wild-type AD 
patients (Cole et al., 2014). We find a modest overlap between transcript and proteomic 
differential markers (Supplementary information). Non-genetic potential disease factors 
including microbiome diversity and epigenetic factors like DNA methylation have only 
recently begun to be investigated (Kong et al., 2012, Rodriguez et al., 2014). The data 
presented here demonstrate alterations in the protein post-translational modification profile 
of patients with AD lesions which ultimately adds another dimension to the rich and 
complex etiology of AD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Fractional citrullination (modifications per arginine) for selected proteins. Many proteins 
related to epidermal differentiation and homeostasis decrease in citrullination with 
perturbation. The unrelated but highly citrullinated protein trichohyalin (TCHH) shows little 
change with condition.
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Figure 2. 
A) Differentially identified proteins (p < 0.05) from Fisher’s exact test. Bar lengths indicate 
the observations by clinical condition. Proteins with the 5 lowest p-values are shown for 
each condition. The full data table is in Supplementary file S2. B) Differentially abundant 
proteins (adjusted p < 0.05) for healthy vs. atopic (nonlesional and lesional) samples. Bars 
represent the difference in average Normalized Spectral Index by clinical condition. Positive 
values indicate higher abundance in atopic samples and negative values indicate higher 
abundance in healthy samples.
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